QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

Hookipa Pharma Stock Price, News & Analysis (NASDAQ:HOOK)

$0.53
+0.01 (+1.93%)
(As of 11/28/2023 ET)
Compare
Today's Range
$0.49
$0.55
50-Day Range
$0.42
$0.63
52-Week Range
$0.41
$2.05
Volume
400,879 shs
Average Volume
644,208 shs
Market Capitalization
$44.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.83

Hookipa Pharma MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
1,005.0% Upside
$5.83 Price Target
Short Interest
Healthy
0.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.02) to ($0.97) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

213th out of 949 stocks

Pharmaceutical Preparations Industry

86th out of 435 stocks


HOOK stock logo

About Hookipa Pharma Stock (NASDAQ:HOOK)

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

HOOK Stock Price History

HOOK Stock News Headlines

HOOKIPA Pharma: HB-500 IND Application Gets FDA Clearance To Treat HIV
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
Analyst Ratings for HOOKIPA Pharma
RBC Capital Keeps Their Buy Rating on Hookipa Pharma (HOOK)
HOOKIPA Announces Executive Leadership Change
RBC Capital Reaffirms Their Buy Rating on Hookipa Pharma (HOOK)
See More Headlines
Receive HOOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hookipa Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
11/28/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/20/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HOOK
Employees
56
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$5.83
High Stock Price Target
$7.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+1,005.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-64,920,000.00
Net Margins
-336.12%
Pretax Margin
-334.01%

Debt

Sales & Book Value

Annual Sales
$20.55 million
Book Value
$1.87 per share

Miscellaneous

Free Float
80,088,000
Market Cap
$44.32 million
Optionable
Not Optionable
Beta
0.75
The Best High-Yield Dividend Stocks for 2023 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report














HOOK Stock Analysis - Frequently Asked Questions

Should I buy or sell Hookipa Pharma stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hookipa Pharma in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HOOK shares.
View HOOK analyst ratings
or view top-rated stocks.

What is Hookipa Pharma's stock price target for 2024?

4 Wall Street research analysts have issued 1-year target prices for Hookipa Pharma's shares. Their HOOK share price targets range from $4.00 to $7.00. On average, they anticipate the company's share price to reach $5.83 in the next twelve months. This suggests a possible upside of 1,005.0% from the stock's current price.
View analysts price targets for HOOK
or view top-rated stocks among Wall Street analysts.

How have HOOK shares performed in 2023?

Hookipa Pharma's stock was trading at $0.81 at the beginning of the year. Since then, HOOK stock has decreased by 34.8% and is now trading at $0.5279.
View the best growth stocks for 2023 here
.

When is Hookipa Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our HOOK earnings forecast
.

How were Hookipa Pharma's earnings last quarter?

Hookipa Pharma Inc (NASDAQ:HOOK) posted its earnings results on Friday, November, 12th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by $0.09. The business earned $3.87 million during the quarter, compared to analysts' expectations of $5.24 million. Hookipa Pharma had a negative trailing twelve-month return on equity of 70.24% and a negative net margin of 336.12%. During the same period last year, the company earned ($0.53) earnings per share.

What other stocks do shareholders of Hookipa Pharma own?
When did Hookipa Pharma IPO?

(HOOK) raised $100 million in an IPO on Thursday, April 18th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, SVB Leerink and RBC Capital Markets acted as the underwriters for the IPO and Kempen was co-manager.

Who are Hookipa Pharma's major shareholders?

Hookipa Pharma's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (4.42%), FMR LLC (4.00%), Redmile Group LLC (1.27%), Group One Trading L.P. (0.00%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Igor Matushansky, Jorn Aldag, Reinhard Kandera and Sofinnova Capital Vi Fcpr.
View institutional ownership trends
.

How do I buy shares of Hookipa Pharma?

Shares of HOOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:HOOK) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -